NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
GREENAllstar Pro® reusable insulin pen  Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
GREENBiphasic Insulin Aspart
(100units/mL)
 
Endocrine system, Biphasic insulins, 06.01.01.02
GREENBiphasic Insulin Lispro
(100units/mL)
 
Endocrine system, Biphasic insulins, 06.01.01.02
 Biphasic Isophane Insulin (HUMAN)
(100units/mL)
 
Endocrine system, Biphasic insulins, 06.01.01.02
GREENHumaPen Savvio® reusable insulin pen  Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
GREENInsulin Aspart Novorapid®
(100units/mL )
 
Endocrine system, Short-acting insulins, 06.01.01.01
GREENInsulin aspart biosimilar Pre-filled pen Trurapi® Endocrine system, Short-acting insulins, 06.01.01.01
Amber SPAInsulin Aspart® Fiasp
(Injection)
 
Endocrine system, Short-acting insulins, 06.01.01.01
Amber SPAInsulin degludec
(100units/mL)
 
Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
Amber SPAInsulin degludec
(200units/mL)
 
Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
GREENInsulin Detemir
(100units/mL)
 
Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
GREENInsulin Glargine
(100units/mL)
 
Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
Amber SPAInsulin Glargine Toujeo®
(300units/mL )
 
Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
GREENInsulin Glulisine
(100units/mL)
 
Endocrine system, Short-acting insulins, 06.01.01.01
GREENInsulin Lispro
(100 units/ml)
 
Endocrine system, Short-acting insulins, 06.01.01.01
Amber SPAInsulin Lispro 200 units/ml Endocrine system, Short-acting insulins, 06.01.01.01
Amber SPAInsulin Lispro Lyumjev®
(100 units/ml, 200 units/ml)
 
Endocrine system, Short-acting insulins, 06.01.01.01
Amber SPAInsulin Lispro 100 units/ml
(0.5 unit pens)
 
Endocrine system, Short-acting insulins, 06.01.01.01
GREENInsulin soluble (HUMAN)
(100units/mL)
 
Endocrine system, Short-acting insulins, 06.01.01.01
GREENIsophane Insulin (HUMAN)
(100units/mL)
 
Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
GREENJunior Star® reusable insulin pen  Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
GREENMyPen2® reusable insulin pen  Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
GREENNovopen 6® and Novopen Echo Plus® reusable insulin pen  Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
GREENCanagliflozin
(For patients with Type 2 diabetes)
 
Endocrine system, SGLT2 inhibitors, 06.01.02.03
GREENDapagliflozin
(For patients with Type 2 diabetes)
 
Endocrine system, SGLT2 inhibitors, 06.01.02.03
GREENEmpagliflozin
(For patients with Type 2 diabetes)
 
Endocrine system, SGLT2 inhibitors, 06.01.02.03
GREENErtugliflozin Steglatro®
(For patients with Type 2 diabetes)
 
Endocrine system, SGLT2 inhibitors, 06.01.02.03
Amber SPAReal time continuous glucose monitoring system FreeStyle Libre 3 Plus®  Endocrine system, Blood glucose monitoring, 06.01.06
Non Formulary items found
Status Description Section
 Needle free insulin delivery system Injex® and InsuJet®.  Miscellaneous, Medical Devices and other products, 16.01
 Pork derived Insulins Hypurin® Endocrine system, Intermediate- and long-acting insulins, 06.01.01.02
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Biphasic  Biphasic Insulin Aspart Endocrine System, Insulins, Insulins, Intermediate-Acting Combined With Rapid-Acting
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Biphasic  Biphasic Insulin Lispro Endocrine System, Insulins, Insulins, Intermediate-Acting Combined With Rapid-Acting
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Insulin  Insulin Aspart Endocrine System, Insulins, Insulins, Rapid-Acting
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Insulin  Insulin Degludec Endocrine System, Insulins, Insulins, Long-Acting
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Insulin  Insulin Degludec With Liraglutide Endocrine System, Insulins, Insulins, Long-Acting
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Insulin  Insulin Detemir Endocrine System, Insulins, Insulins, Long-Acting
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Insulin  Insulin Glargine Endocrine System, Insulins, Insulins, Long-Acting
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Insulin  Insulin Glargine With Lixisenatide Endocrine System, Blood Glucose Lowering Drugs, Glucagon-Like Peptide-1 Receptor Agonists
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Insulin  Insulin Glargine With Lixisenatide Endocrine System, Insulins, Insulins, Long-Acting
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Insulin  Insulin Glulisine Endocrine System, Insulins, Insulins, Rapid-Acting
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Insulin  Insulin Lispro Endocrine System, Insulins, Insulins, Rapid-Acting
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Links found
APC Bulletin 5 (March 2023): Insulin Degludec (Tresiba®)
APC Bulletin 6 (March 2023): Insulin glargine 300 units/ml (Toujeo®)
CAS Alert Dec 2023 Potential for inappropriate dosing of insulin when switching insulin degludec (Tresiba) products
Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on reporting suspected adverse incidents and safety concerns to the MHRA’s Yellow Card scheme
JPC Bulletin 240 (June 2016): High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error - Safety Reminder
Medicine Supply Notification: Various Insuman Insulin preparations discontinued Jan 2023
MHRA Drug Safety Update (April 2013) - Insulin degludec (Tresiba▼): available in additional higher strength
MHRA Drug Safety Update (April 2013) - Insulin degludec (Tresiba▼): available in additional higher strength
MHRA Drug Safety Update (January 2011) - Insulin combined with pioglitazone: risk of cardiac failure
MHRA DSU GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
MHRA DSU June 2019: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
MHRA DSU June 2019: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
NICE TA151: Insulin pumps
NICE TA53: Diabetes (types 1 and 2) - long acting insulin analogues
Reusable Insulin Pen Device Guide - BLMK ICB